

(19) World Intellectual Property Organization  
International Bureau



136

(43) International Publication Date  
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number  
**WO 01/75093 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/00**,  
15/12, C07K 14/435

(21) International Application Number: PCT/US01/10484

(22) International Filing Date: 30 March 2001 (30.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/540,217	31 March 2000 (31.03.2000)	US
09/649,167	23 August 2000 (23.08.2000)	US
09/668,680	22 September 2000 (22.09.2000)	US
09/695,618	23 October 2000 (23.10.2000)	US
09/728,711	30 November 2000 (30.11.2000)	US
Not furnished	14 March 2001 (14.03.2001)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	09/540,217 (CIP)
Filed on	31 March 2000 (31.03.2000)
US	09/649,167 (CIP)
Filed on	23 August 2000 (23.08.2000)
US	09/668,680 (CIP)
Filed on	22 September 2000 (22.09.2000)
US	09/695,618 (CIP)
Filed on	23 October 2000 (23.10.2000)
US	09/728,711 (CIP)
Filed on	30 November 2000 (30.11.2000)
US	Not furnished (CIP)
Filed on	14 March 2001 (14.03.2001)

(71) Applicant (for all designated States except US): **HYSEQ, INC.** [US/US]; 670 Almanor Avenue, Sunnyvale, CA 94086 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TANG, Y., Tom** [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **ASUNDI, Vinod** [US/US]; 709 Foster City Boulevard, Foster City, CA 94404 (US). **ZHOU, Ping** [CN/US]; 7595 Newcastle Drive, Cupertino, CA 95014 (US). **XUE, Aidong, J.** [CN/US]; 1621 S. Mary Avenue, Sunnyvale,

CA 94087 (US). **REN, Feiyan** [US/US]; 7703 Oak Meadow Court, Cupertino, CA 95014 (US). **ZHANG, Jie** [CN/US]; 4930 Poplar Terrace, Campbell, CA 95008 (US). **WANG, Jian-Rue** [CN/US]; 744 Stendhal Lane, Cupertino, CA 95014 (US). **XU, Chongjun** [US/US]; 4918 Manitoba Drive, San Jose, CA 95130 (US). **YANG, Yonghong** [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **ZAHO, Qing, A.** [CN/US]; 1556 Kooser Road, San Jose, CA 95118 (US). **CHEN, Rui-hong** [US/US]; 1031 Flying Fish Street, Foster City, CA 94404 (US). **WANG, Dunrui** [CN/US]; 932 La Palma, Milpitas, CA 95035 (US). **GOODRICH, Ryle, W.** [US/US]; 4896 Sandy Lane, San Jose, CA 95124 (US). **LIU, Chenghua** [CN/US]; 1125 Ranchero Way, Apt. #14, San Jose, CA 95117 (US). **DRMANAC, Radoje, T.** [YU/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US).

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES

(57) Abstract: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.



WO 01/75093 A1

## WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-43, or 87-129, a mature protein coding portion of SEQ ID NO: 1-43, or 87-129, an active domain coding portion of SEQ ID NO: 1-43, or 87-129, and  
5 complementary sequences thereof.
2. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide hybridizes to the polynucleotide of claim 1 under stringent hybridization conditions.  
10
3. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide has greater than about 90% sequence identity with the polynucleotide of claim 1.
4. The polynucleotide of claim 1 wherein said polynucleotide is DNA.  
15
5. An isolated polynucleotide of claim 1 wherein said polynucleotide comprises the complementary sequences.
6. A vector comprising the polynucleotide of claim 1.  
20
7. An expression vector comprising the polynucleotide of claim 1.
8. A host cell genetically engineered to comprise the polynucleotide of claim 1.
- 25 9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.
10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of:  
30
  - (a) a polypeptide encoded by any one of the polynucleotides of claim 1; and
  - (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO: 1-43, or 87-129.
11. A composition comprising the polypeptide of claim 10 and a carrier.  
35

12. An antibody directed against the polypeptide of claim 10.
13. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
- a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and
  - b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.
14. A method for detecting the polynucleotide of claim 1 in a sample, comprising:
- a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;
  - b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and
  - c) detecting said product and thereby the polynucleotide of claim 1 in the sample.
15. The method of claim 14, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.
16. A method for detecting the polypeptide of claim 10 in a sample, comprising:
- a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and
  - b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.
17. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:
- a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and
  - b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.
18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and

b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

19. A method of producing the polypeptide of claim 10, comprising,

a) culturing a host cell comprising a polynucleotide sequence selected from SEQ ID NO: 1-43, or 87-129, a mature protein coding portion of SEQ ID NO: 1-43, or 87-129, an active domain coding portion of SEQ ID NO: 1-43, or 87-129, complementary sequences thereof and a polynucleotide sequence hybridizing under stringent conditions to SEQ ID NO: 1-43, or 87-129, under conditions sufficient to express the polypeptide in said cell; and

b) isolating the polypeptide from the cell culture or cells of step (a).

20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of any one of the polypeptides SEQ ID NO: 44-86, or 130-172, the mature protein portion thereof, or the active domain thereof.

21. The polypeptide of claim 20 wherein the polypeptide is provided on a polypeptide array.

22. A collection of polynucleotides, wherein the collection comprising the sequence information of at least one of SEQ ID NO: 1-43, or 87-129.

23. The collection of claim 22, wherein the collection is provided on a nucleic acid array.

24. The collection of claim 23, wherein the array detects full-matches to any one of the polynucleotides in the collection.

25. The collection of claim 23, wherein the array detects mismatches to any one of the polynucleotides in the collection.

26. The collection of claim 22, wherein the collection is provided in a computer-readable format.

27. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.

5

28. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising an antibody that specifically binds to a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.



Leu Phe Phe Cys Leu Pro Met Ala Ile Met Ser Val Leu Tyr Leu Leu  
 260 265 270  
 att ggg ctg cga ctg cgg cgg gag agg ctg ctg ctc atg cag gag gcc 864  
 Ile Gly Leu Arg Leu Arg Arg Glu Arg Leu Leu Leu Met Gln Glu Ala  
 275 280 285  
 aag ggc agg ggc tct gca gca gcc agg tcc aga tac acc tgc agg ctc 912  
 Lys Gly Arg Gly Ser Ala Ala Ala Arg Ser Arg Tyr Thr Cys Arg Leu  
 290 295 300  
 cag cag cac gat cgg ggc cgg aga caa gtg acc aag atg ctg ttt gtc 960  
 Gln Gln His Asp Arg Gly Arg Arg Gln Val Thr Lys Met Leu Phe Val  
 305 310 315 320  
 ctg gtc gtg gtg ttt ggc atc tgc tgg gcc ccg ttc cac gcc gac cgc 1008  
 Leu Val Val Val Phe Gly Ile Cys Trp Ala Pro Phe His Ala Asp Arg  
 325 330 335  
 gtc atg tgg agc gtc gtg tca cag tgg aca gat ggc ctg cac ctg gcc 1056  
 Val Met Trp Ser Val Val Ser Gln Trp Thr Asp Gly Leu His Leu Ala  
 340 345 350  
 ttc cag cac gtg cac gtc atc tcc ggc atc ttc ttc tac ctg ggc tcg 1104  
 Phe Gln His Val His Val Ile Ser Gly Ile Phe Phe Tyr Leu Gly Ser  
 355 360 365  
 ggc gcc aac ccc gtg ctc tat agc ctc atg tcc agc cgc ttc cga gag 1152  
 Ala Ala Asn Pro Val Leu Tyr Ser Leu Met Ser Ser Arg Phe Arg Glu  
 370 375 380  
 acc ttc cag gag gcc ctg tgc ctc ggg gcc tgc tgc cat cgc ctc aga 1200  
 Thr Phe Gln Glu Ala Leu Cys Leu Gly Ala Cys Cys His Arg Leu Arg  
 385 390 395 400  
 ccc cgc cac agc tcc cac agc ctc agc agg atg acc aca ggc agc acc 1248  
 Pro Arg His Ser Ser His Ser Leu Ser Arg Met Thr Thr Gly Ser Thr  
 405 410 415  
 ctg tgt gat gtg ggc tcc ctg ggc agc tgg gtc cac ccc ctg gct ggg 1296  
 Leu Cys Asp Val Gly Ser Leu Gly Ser Trp Val His Pro Leu Ala Gly  
 420 425 430  
 aac gat ggc cca gag ggc cag caa gag acc gat cca tcc tgagtggagc 1345  
 Asn Asp Gly Pro Glu Ala Gln Gln Glu Thr Asp Pro Ser  
 435 440 445  
 cttaaagtgg cttcacctgg aggggccaga gggtcacctg gagctgggga gacacatctg 1405  
 ccttctctctg cagggatgcc ttcacgtact gtccttagtt cagcctagaa attctgacca 1465  
 gcacctcagt ttccttcaga gggaaacagc aggaggaggg atccctgact gctgaggact 1525  
 cacactgacc 1535

<210> 11  
 <211> 1539  
 <212> DNA  
 <213> Homo sapiens  
 <220>





&lt;221&gt; CDS

&lt;222&gt; (130)..(1536)

&lt;400&gt; 11

```

gcacgaggtg gaggacgcgg ctgcttcaag tcttggctc tgatccaggc cacagattcc      60
aggattctac aggcaggaaa catcttagaa atcagggttg ggcaggcagg agccaggaga      120
gtagctaca   atg act tca cca gta ctg gtg gac ata cga gaa gag gtg      168
              Met Thr Ser Pro Val Leu Val Asp Ile Arg Glu Glu Val
              1             5             10

acc tgc cct atc tgc ctg gag ctc cta aca gaa ccc ctg agc ata gac      216
Thr Cys Pro Ile Cys Leu Glu Leu Leu Thr Glu Pro Leu Ser Ile Asp
              15             20             25

tgt ggc cac agc ttc tgc caa gcc tgc atc aca cca aat ggc agg gaa      264
Cys Gly His Ser Phe Cys Gln Ala Cys Ile Thr Pro Asn Gly Arg Glu
              30             35             40             45

tca gtg att ggt caa gaa ggg gaa aga agc tgc cct gtg tgc cag acc      312
Ser Val Ile Gly Gln Glu Gly Glu Arg Ser Cys Pro Val Cys Gln Thr
              50             55             60

agc tac cag cca ggg aac ctg cgg cct aat cgg cat ctg gcc aac ata      360
Ser Tyr Gln Pro Gly Asn Leu Arg Pro Asn Arg His Leu Ala Asn Ile
              65             70             75

gtg agg cgg ctc aga gag gta gtg ttg ggc cct ggg aag cag ctg aaa      408
Val Arg Arg Leu Arg Glu Val Val Leu Gly Pro Gly Lys Gln Leu Lys
              80             85             90

gca gtt ctt tgt gca gac cat gga gaa aaa ctg cag ctc ttc tgt cag      456
Ala Val Leu Cys Ala Asp His Gly Glu Lys Leu Gln Leu Phe Cys Gln
              95             100             105

gag gat ggg aag gag aag ttt cag gag tct cta aag aag ctg aag aac      504
Glu Asp Gly Lys Glu Lys Phe Gln Glu Ser Leu Lys Lys Leu Lys Asn
              110             115             120             125

gag gag cag gaa gct gag aag cta aca gct ttt atc aga gag aag aag      552
Glu Glu Gln Glu Ala Glu Lys Leu Thr Ala Phe Ile Arg Glu Lys Lys
              130             135             140

aca tcc tgg aag gca agg gag act ttt tct gaa gat gtc ctg ggg cag      600
Thr Ser Trp Lys Ala Arg Glu Thr Phe Ser Glu Asp Val Leu Gly Gln
              145             150             155

gaa tca tgg cag agt aca aat gca agg gaa aat gca ggg atc cca ggg      648
Glu Ser Trp Gln Ser Thr Asn Ala Arg Glu Asn Ala Gly Ile Pro Gly
              160             165             170

ctg gag gct gcc cac ttc tgg att gcc atc cct ttc tgt gcc atg tat      696
Leu Glu Ala Ala His Phe Trp Ile Ala Ile Pro Phe Cys Ala Met Tyr
              175             180             185

ctt gta gca ctg gtt gga aat gct gcc ctc atc ctg gtc att gcc atg      744
Leu Val Ala Leu Val Gly Asn Ala Ala Leu Ile Leu Val Ile Ala Met
              190             195             200             205

gac aat gct ctt cat gca cct atg tac ctc ttc ctc tgc ctt ctc tca      792
Asp Asn Ala Leu His Ala Pro Met Tyr Leu Phe Leu Cys Leu Ser
              210             215             220

```

The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the transparency and accountability of the organization. The document then outlines the specific procedures for recording transactions, including the use of standardized forms and the requirement for double-checking entries.

The second part of the document addresses the issue of budgeting and financial planning. It explains how the organization should set realistic financial goals and develop a detailed budget for each fiscal year. The document also discusses the importance of regularly reviewing the budget and making adjustments as needed to ensure that the organization remains on track.

The third part of the document focuses on the management of assets and liabilities. It provides guidelines for the proper valuation and depreciation of assets, as well as the methods for recording and reporting liabilities. The document also discusses the importance of maintaining accurate records of all asset and liability transactions.

The fourth part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the transparency and accountability of the organization. The document then outlines the specific procedures for recording transactions, including the use of standardized forms and the requirement for double-checking entries.

The fifth part of the document addresses the issue of budgeting and financial planning. It explains how the organization should set realistic financial goals and develop a detailed budget for each fiscal year. The document also discusses the importance of regularly reviewing the budget and making adjustments as needed to ensure that the organization remains on track.

The sixth part of the document focuses on the management of assets and liabilities. It provides guidelines for the proper valuation and depreciation of assets, as well as the methods for recording and reporting liabilities. The document also discusses the importance of maintaining accurate records of all asset and liability transactions.

The seventh part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the transparency and accountability of the organization. The document then outlines the specific procedures for recording transactions, including the use of standardized forms and the requirement for double-checking entries.

The eighth part of the document addresses the issue of budgeting and financial planning. It explains how the organization should set realistic financial goals and develop a detailed budget for each fiscal year. The document also discusses the importance of regularly reviewing the budget and making adjustments as needed to ensure that the organization remains on track.

The ninth part of the document focuses on the management of assets and liabilities. It provides guidelines for the proper valuation and depreciation of assets, as well as the methods for recording and reporting liabilities. The document also discusses the importance of maintaining accurate records of all asset and liability transactions.

The tenth part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that proper record-keeping is essential for the transparency and accountability of the organization. The document then outlines the specific procedures for recording transactions, including the use of standardized forms and the requirement for double-checking entries.

etc aca gac ctg gct ctc agt tct acc act gtg ccc aag atg ctg gcc 840  
 Leu Thr Asp Leu Ala Leu Ser Ser Thr Thr Val Pro Lys Met Leu Ala  
 225 230 235

att ttg tgg ctc cat gct ggt gag att tcc ttt ggt gga tgc ctg gcc 888  
 ile Leu Trp Leu His Ala Gly Glu Ile Ser Phe Gly Gly Cys Leu Ala  
 240 245 250

cag atg ttt tgt gtc cat tct atc tat gct ctg gag tcc tcg att cta 936  
 Gln Met Phe Cys Val His Ser Ile Tyr Ala Leu Glu Ser Ser Ile Leu  
 255 260 265

ctt gcc atg gcc ttt gat agg tat gtg gct atc tgt aac cca tta agg 984  
 Leu Ala Met Ala Phe Asp Arg Tyr Val Ala Ile Cys Asn Pro Leu Arg  
 270 275 280 285

tat aca acc att ctc aac cat gct gtc ata ggc aga att ggc ttt gtt 1032  
 Tyr Thr Thr Ile Leu Asn His Ala Val Ile Gly Arg Ile Gly Phe Val  
 290 295 300

ggg cta ttc cgt agt gtg gct att gtc tcc ccc ttc atc ttc ttg ctg 1080  
 Gly Leu Phe Arg Ser Val Ala Ile Val Ser Pro Phe Ile Phe Leu Leu  
 305 310 315

agg cga ctc ccc tac tgt ggt cac cgt gtc atg aca cac aca tac tgt 1128  
 Arg Arg Leu Pro Tyr Cys Gly His Arg Val Met Thr His Thr Tyr Cys  
 320 325 330

gag cat atg ggc atc gcc cga ctg gcc tgt gcc aac atc act gtc aat 1176  
 Glu His Met Gly Ile Ala Arg Leu Ala Cys Ala Asn Ile Thr Val Asn  
 335 340 345

att gtc tat ggg cta act gtg gct ctg ctg gcc atg gga ctg gat tcc 1224  
 ile Val Tyr Gly Leu Thr Val Ala Leu Leu Ala Met Gly Leu Asp Ser  
 350 355 360 365

att ctc att gcc att tcc tat ggc ttt atc ctc cat gca gtc ttt cac 1272  
 ile Leu ile Ala ile Ser Tyr Gly Phe ile Leu His Ala Val Phe His  
 370 375 380

ctt cca tct cat gat gcc cag cac aaa gct ctg agt acc tgt ggc tcc 1320  
 Leu Pro Ser His Asp Ala Gln His Lys Ala Leu Ser Thr Cys Gly Ser  
 385 390 395

cac att ggc atc atc ctg gtt ttc tac atc cct gcc ttc ttc tcc ttc 1368  
 His ile Gly ile ile Leu Val Phe Tyr ile Pro Ala Phe Phe Ser Phe  
 400 405 410

ctc acc cac cgc ttt ggt cac cac gaa gtc ccc aag cat gtg cac atc 1416  
 Leu Thr His Arg Phe Gly His His Glu Val Pro Lys His Val His ile  
 415 420 425

ttt ctg gct aat ctc tat gtg ctg gtg cct cct gta ctc aat cct att 1464  
 Phe Leu Ala Asn Leu Tyr Val Leu Val Pro Pro Val Leu Asn Pro ile  
 430 435 440 445

ctc tat gga gct aga acc aag gag att cgg agt cga ctt cta aaa ctg 1512  
 Leu Tyr Gly Ala Arg Thr Lys Glu ile Arg Ser Arg Leu Leu Lys Leu  
 450 455 460

ctt cac ctg ggg aag act tca ata tga 1539  
 Leu His Leu Gly Lys Thr Ser ile  
 465



Thr Arg Ala His Val Arg Arg Val Leu Gly Ala Val Trp Gly Leu Ala  
 195 200 205  
 Met Leu Cys Ser Leu Pro Asn Thr Ser Leu His Gly Ile Arg Gln Leu  
 210 215 220  
 His Val Pro Cys Arg Gly Pro Val Pro Asp Ser Ala Val Cys Met Leu  
 225 230 235 240  
 Val Pro Pro Arg Ala Leu Tyr Asn Met Val Val Gln Thr Thr Ala Leu  
 245 250 255  
 Leu Phe Phe Cys Leu Pro Met Ala Ile Met Ser Val Leu Tyr Leu Leu  
 260 265 270  
 Ile Gly Leu Arg Leu Arg Arg Glu Arg Leu Leu Leu Met Gln Glu Ala  
 275 280 285  
 Lys Gly Arg Gly Ser Ala Ala Ala Arg Ser Arg Tyr Thr Cys Arg Leu  
 290 295 300  
 Gln Gln His Asp Arg Gly Arg Arg Gln Val Thr Lys Met Leu Phe Val  
 305 310 315 320  
 Leu Val Val Val Phe Gly Ile Cys Trp Ala Pro Phe His Ala Asp Arg  
 325 330 335  
 Val Met Trp Ser Val Val Ser Gln Trp Thr Asp Gly Leu His Leu Ala  
 340 345 350  
 Phe Gln His Val His Val Ile Ser Gly Ile Phe Phe Tyr Leu Gly Ser  
 355 360 365  
 Ala Ala Asn Pro Val Leu Tyr Ser Leu Met Ser Ser Arg Phe Arg Glu  
 370 375 380  
 Thr Phe Gln Glu Ala Leu Cys Leu Gly Ala Cys Cys His Arg Leu Arg  
 385 390 395 400  
 Pro Arg His Ser Ser His Ser Leu Ser Arg Met Thr Thr Gly Ser Thr  
 405 410 415  
 Leu Cys Asp Val Gly Ser Leu Gly Ser Trp Val His Pro Leu Ala Gly  
 420 425 430  
 Asn Asp Gly Pro Glu Ala Gln Gln Glu Thr Asp Pro Ser  
 435 440 445

<210> 54  
 <211> 469  
 <212> PRT  
 <213> Homo sapiens

<400> 54  
 Met Thr Ser Pro Val Leu Val Asp Ile Arg Glu Glu Val Thr Cys Pro  
 1 5 10 15  
 Ile Cys Leu Glu Leu Leu Thr Glu Pro Leu Ser Ile Asp Cys Gly His  
 20 25 30  
 Ser Phe Cys Gln Ala Cys Ile Thr Pro Asn Gly Arg Glu Ser Val Ile  
 35 40 45  
 Gly Gln Glu Gly Glu Arg Ser Cys Pro Val Cys Gln Thr Ser Tyr Gln  
 50 55 60  
 Pro Gly Asn Leu Arg Pro Asn Arg His Leu Ala Asn Ile Val Arg Arg  
 65 70 75 80  
 Leu Arg Glu Val Val Leu Gly Pro Gly Lys Gln Leu Lys Ala Val Leu  
 85 90 95  
 Cys Ala Asp His Gly Glu Lys Leu Gln Leu Phe Cys Gln Glu Asp Gly  
 100 105 110  
 Lys Glu Lys Phe Gln Glu Ser Leu Lys Lys Leu Lys Asn Glu Glu Gln  
 115 120 125  
 Glu Ala Glu Lys Leu Thr Ala Phe Ile Arg Glu Lys Lys Thr Ser Trp  
 130 135 140  
 Lys Ala Arg Glu Thr Phe Ser Glu Asp Val Leu Gly Gln Glu Ser Trp  
 145 150 155 160  
 Gln Ser Thr Asn Ala Arg Glu Asn Ala Gly Ile Pro Gly Leu Glu Ala  
 165 170 175



Ala His Phe Trp Ile Ala Ile Pro Phe Cys Ala Met Tyr Leu Val Ala  
 180 185 190  
 Leu Val Gly Asn Ala Ala Leu Ile Leu Val Ile Ala Met Asp Asn Ala  
 195 200 205  
 Leu His Ala Pro Met Tyr Leu Phe Leu Cys Leu Leu Ser Leu Thr Asp  
 210 215 220  
 Leu Ala Leu Ser Ser Thr Thr Val Pro Lys Met Leu Ala Ile Leu Trp  
 225 230 235 240  
 Leu His Ala Gly Glu Ile Ser Phe Gly Gly Cys Leu Ala Gln Met Phe  
 245 250 255  
 Cys Val His Ser Ile Tyr Ala Leu Glu Ser Ser Ile Leu Leu Ala Met  
 260 265 270  
 Ala Phe Asp Arg Tyr Val Ala Ile Cys Asn Pro Leu Arg Tyr Thr Thr  
 275 280 285  
 Ile Leu Asn His Ala Val Ile Gly Arg Ile Gly Phe Val Gly Leu Phe  
 290 295 300  
 Arg Ser Val Ala Ile Val Ser Pro Phe Ile Phe Leu Leu Arg Arg Leu  
 305 310 315 320  
 Pro Tyr Cys Gly His Arg Val Met Thr His Thr Tyr Cys Glu His Met  
 325 330 335  
 Gly Ile Ala Arg Leu Ala Cys Ala Asn Ile Thr Val Asn Ile Val Tyr  
 340 345 350  
 Gly Leu Thr Val Ala Leu Leu Ala Met Gly Leu Asp Ser Ile Leu Ile  
 355 360 365  
 Ala Ile Ser Tyr Gly Phe Ile Leu His Ala Val Phe His Leu Pro Ser  
 370 375 380  
 His Asp Ala Gln His Lys Ala Leu Ser Thr Cys Gly Ser His Ile Gly  
 385 390 395 400  
 Ile Ile Leu Val Phe Tyr Ile Pro Ala Phe Phe Ser Phe Leu Thr His  
 405 410 415  
 Arg Phe Gly His His Glu Val Pro Lys His Val His Ile Phe Leu Ala  
 420 425 430  
 Asn Leu Tyr Val Leu Val Pro Pro Val Leu Asn Pro Ile Leu Tyr Gly  
 435 440 445  
 Ala Arg Thr Lys Glu Ile Arg Ser Arg Leu Leu Lys Leu Leu His Leu  
 450 455 460  
 Gly Lys Thr Ser Ile  
 465

<210> 55  
 <211> 195  
 <212> PRT  
 <213> Homo sapiens

<400> 55  
 Met Gly Arg Ala Arg Asp Ala Ile Leu Asp Ala Leu Glu Asn Leu Thr  
 1 5 10 15  
 Ala Glu Glu Leu Lys Lys Phe Lys Leu Lys Leu Leu Ser Val Pro Leu  
 20 25 30  
 Arg Glu Gly Tyr Gly Arg Ile Pro Arg Gly Ala Leu Leu Ser Met Asp  
 35 40 45  
 Ala Leu Asp Leu Thr Asp Lys Leu Val Ser Phe Tyr Leu Glu Thr Tyr  
 50 55 60  
 Gly Ala Glu Leu Thr Ala Asn Val Leu Arg Asp Met Gly Leu Gln Glu  
 65 70 75 80  
 Met Ala Gly Gln Leu Gln Ala Ala Thr His Gln Gly Ser Gly Ala Ala  
 85 90 95  
 Pro Ala Gly Ile Gln Ala Pro Pro Gln Ser Ala Ala Lys pro Gly Leu  
 100 105 110  
 His Phe Ile Asp Gln His Arg Ala Ala Leu Ile Ala Arg Val Thr Asn  
 115 120 125

